United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$275.13 USD
+4.68 (1.73%)
Updated May 31, 2024 04:00 PM ET
After-Market: $275.22 +0.09 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 241 - 260 ( 589 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Arena Deal Validates United Therapeutics Commitment to PAH in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Financials; NextGen PAH Pipeline Continues to Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Something Has to Change; Reit Neutral and $95 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Science Day: Encouraging Update on Next Gen PAH Products
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Strategic Collaboration with MannKind Broadens Treatment Options for PAH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Settlement Extends Tyvaso to 2026; However, Innovation Likely More Impactful
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Positive FREEDOM-EV: Suggests to Us Potential for Orenitram Sales Acceleration
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Top and Bottom Line Beat as Generics Delay Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L